Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. — Stella

Home/Relapsed or Refractory Multiple Myeloma/A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

View on ClinicalTrials.gov

Recruiting

Back to Relapsed or Refractory Multiple Myeloma trials

A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Institute of Hematology and Blood Diseases Hospital, Beijing

Key details

Phase

Early testing / Safety & dosing

Sponsor

Beijing Mabworks Biotech Co., Ltd.

Enrollment target

~154 participants

Started

February 2024

Primary completion

February 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated March 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.